• Approximately 12,000 square meters
• Commercial 、Clinical and Vector manufacturing
• Six independent modules with design capacity of up to 2,500 batches of autologous CAR-T products per year (can support autologous CAR-T therapies for up to around 2,500 patients per year)
• In compliance with cGMP and QMS standards

End-To-End Process and Traceability Management

• To meet the management requirements of autologous CAR-T drugs over the whole process, JW Therapeutics designed the end-to-end traceability system (COI/COC system), covering up to 19 control nodes, which also connects with the MES system (Manufacturing Execution System), together with SAP system(ERP) and LIMS system( Laboratory Information Management System) ,to build a set of traceability systems that comply with GMP standards, and truly achieve digital and systematic real-time monitoring, traceability and management.

Information as of: March 2025